DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy
for prostate cancer. JAMA, 2005, 294:238–244.
Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal
alone or in combination with ketoconazole in androgenindependent
prostate cancer patients: A phase III trial
(CALGB 9583). J Clin Oncol, 2004, 22:1025–1033.
Smith MR. Treatment-related diabetes and cardiovascular disease
in prostate cancer survivors. Ann Oncol, 2008, 19: vii86–vii90.
Smith MR, Egerdie B, Toriz NH, et al. Denosumab in men
receiving androgen-deprivation therapy for prostate cancer.
N Engl J Med, 2009, 361:745–755.
Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of
genes converting adrenal androgens to testosterone in androgenindependent
prostate cancer. Cancer Res, 2006, 66:2815–2825.
Swedish Breast Cancer Cooperative Group. Randomized trial of
two versus five years of adjuvant tamoxifen for postmenopausal
early stage breast cancer. J Natl Cancer Inst,
1996, 88:1543–1549.
Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone
or mitoxantrone plus prednisone for advanced prostate
cancer. N Engl J Med, 2004, 351:1502–1512.
Thorpe SC, Azmatullah S, Fellows GJ, et al. A prospective, randomised
study to compare goserelin acetate (Zoladex) versus
cyproterone acetate (Cyprostat) versus a combination of the
two in the treatment of metastatic prostatic carcinoma. Eur
Urol, 1996, 29:47–54.
Thürlimann B, Keshaviah A, Coates AS, et al. A comparison of
letrozole and tamoxifen in postmenopausal women with early
breast cancer. N Engl J Med, 2005, 353:2747–2757.
Tolis G, Ackman D, Stellos A, et al. Tumor growth inhibition
in patients with prostatic carcinoma treated with luteinizing
hormone-releasing hormone agonists. Proc Natl Acad Sci U S A,
1982, 79:1658–1662.
Trachtenberg J, Gittleman M, Steidle C, et al. A phase 3, multicenter,
open label, randomized study of abarelix versus leuprolide
plus daily antiandrogen in men with prostate cancer.
J Urol, 2002, 167:1670–1674.
Turkes AO, Peeling WB, Griffiths K. Treatment of patients with
advanced cancer of the prostate: Phase III trial, Zoladex
against castration; a study of the British Prostate Group.
J Steroid Biochem, 1987, 27:543–549.
Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomised comparison
of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus
castration in the treatment of metastatic and locally advanced
prostate cancer. Eur Urol, 1998, 33:447–456.
Vergote I, Robertson JF. Fulvestrant is an effective and welltolerated
endocrine therapy for postmenopausal women
with advanced breast cancer: Results from clinical trials.
Br J Cancer, 2004, 90:S11–S14.
Vogel VG, Constantino JP, Wickenham DL, et al. Update of the
National Surgical Adjuvant Brest and Bowel Project Study of
Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing
breast cancer. Cancer Prev, 2010; PMID: 20404000.
Vogelzang NJ, Chodak GW, Soloway MS, et al. Goserelin versus
orchiectomy in the treatment of advanced prostate cancer: Final
results of a randomized trial. Urology, 1995, 46: 220–226.
Walsh PC, Deweese TL, Eisenberger MA. A structured debate:
immediate vs. deferred androgen suppression in prostate cancer:
Evidence for deferred treatment. J Urol, 2001, 166:
508–516.
Waxman J, Man A, Hendry WF, et al. Importance of early
tumour exacerbation in patients treated with long acting analogues
of gonadotrophin releasing hormone for advanced prostatic
cancer. Br Med J, 1985, 291:1387–1388.
Waymont B, Lynch TH, Dunn JA, et al. Phase III randomised
study of Zoladex versus stilboestrol in the treatment of
advanced prostate cancer. Br J Urol, 1992, 69:614–620.
Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J Urol,
1996, 155:209–212.
Wysowski DK, Freiman JP, Tourtelot JB, Horton ML. Fatal and
nonfatal hepatotoxicity associated with flutamide. Ann Intern
Med, 1993, 118:860–864.
1769
CHAPTER 63
NATURAL PRODUCTS IN CANCER CHEMOTHERAPY: HORMONES AND RELATED AGENTS